Abbonarsi

Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: A 16-Year Australian Single Centre Experience - 25/01/19

Doi : 10.1016/j.hlc.2017.09.014 
Jason Nogic, MBBS, Youlin Koh, MBBS, Marek Bak, MBBS, Robert P. Gooley, MBBS, PhD, Ian T. Meredith, MBBS, PhD, MD, Liam M. McCormick, MBBS, MD
 Monash Cardiovascular Research Centre, MonashHeart, Monash Health, Monash Medical Centre, Melbourne, Vic, Australia 

Corresponding author at: Monash Cardiovascular Research Centre, MonashHeart, Monash Health, Monash Medical Centre, 246 Clayton Road, Clayton 3168, Melbourne, Australia. Tel.: +61 03 9594 6666.Monash Cardiovascular Research Centre, MonashHeart, Monash Health, Monash Medical Centre, 246 Clayton Road, Clayton 3168, Melbourne, Australia. Tel.: +61 03 9594 6666.

Riassunto

Background

Alcohol septal ablation (ASA), is a well-established treatment for symptomatic hypertrophic obstructive cardiomyopathy (HOCM). We report the acute, short and long-term clinical and echocardiographic outcomes of our experience in a single Australian centre over 16 years.

Methods

We retrospectively analysed consecutive patients presenting to our centre for ASA between March 2000 and July 2016. Local databases were interrogated along with direct patient or physician contact occurred where required.

Results

Alcohol septal ablation was performed in 80 patients with symptomatic, medication refractory HOCM (mean age 61±15 years; range 22–84 years; 50% male). All patients had transthoracic echocardiography prior to the procedure, within 48hours of the procedure, 6 weeks, 6 months, 1 year and yearly thereafter to a median follow-up of 80±40months. At baseline, mean resting and provoked LVOT gradients were 80±49mmHg and 97±40mmHg respectively. Compared with baseline, ASA led to a reduction in resting LVOT gradients at all time points, particularly at 2 days—52±41mmHg, p<0.001; 12 months—29±34mmHg, p<0.001; and last follow-up 12±21mmHg, p<0.001. Provoked LVOT gradients were also reduced at 2 days—64±44mmHg and last follow-up of 19±29mmHg, p<0.001. Compared to baseline (19.8±4.2mm), ASA was associated with a reduction in interventricular septal (IVS) thickness at all time intervals with last echocardiographic follow-up at 80 months being 16.0±4.9mm, (<p=0.001). The incidence of new RBBB was 27% and pacemakers were inserted in 24% of patients due to complete heart block. There was 1 (1.1%) in hospital death. At last clinical follow-up at 93 months (IQR 86–100) there was a significant reduction in mean NYHA class from 2.5 to 1.1 (p=<0.05) and reduction in the incidence of pre-syncope of 23% vs 3% (p=0.005).

Conclusions

In correctly selected patients, ASA is a safe and efficacious procedure resulting in significant reduction of LVOT gradient, clinical symptoms and IVS thickness. The largest effect occurs in the first year post procedure, however ongoing decrease of LVOT gradient and symptoms can be seen many years post ablation.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : Hypertrophic obstructive cardiomyopathy (HOCM), Percutaneous transluminal septal myocardial ablation (PTSMA), LVOT gradient, Alcohol septal ablation (ASA)


Mappa


© 2017  Pubblicato da Elsevier Masson SAS.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 27 - N° 12

P. 1446-1453 - dicembre 2018 Ritorno al numero
Articolo precedente Articolo precedente
  • Drug-Eluting Stents Versus Coronary Artery Bypass Grafts for Left Main Coronary Disease: A Meta-Analysis and Review of Randomised Controlled Trials
  • Peter Moore, Matthew Burrage, Paul Garrahy, Richard Lim, Andrew McCann, Anthony Camuglia
| Articolo seguente Articolo seguente
  • Evaluation of Cognitive Function Following Transcatheter Aortic Valve Replacement
  • Masieh Abawi, Rehana de Vries, Pieter R. Stella, Pierfrancesco Agostoni, Dirk H.M. Boelens, Romy C. van Jaarsveld, Charlotte S. van Dongen, Pieter A.F.M. Doevendans, Mariëlle H. Emmelot-Vonk

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.